Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab
Authors:
- M. FakihMFM. Fakih
- F. CiardielloFCF. Ciardiello
- G.W. PragerGPG.W. Prager
- E. ÉlezEÉE. Élez
- E. CallejaECE. Calleja
- N. Caussé-AmellalNCN. Caussé-Amellal
- J. TaiebJTJ. Taieb
- E. Van CutsemECE. Van Cutsem
Open Access
- 16 June 2025
- journal article
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- 532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD studyAnnals of Oncology, 2024
- 35P Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trialAnnals of Oncology, 2024
- Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living GuidelineAnnals of Oncology, 2023
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2023
- Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancerESMO Open, 2022
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Cardiotoxicities of 5-Fluorouracil and Other FluoropyrimidinesCurrent Treatment Options in Oncology, 2020
- Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UKBritish Journal of Cancer, 2019
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Bevacizumab toxicities and their management in ovarian cancerGynecologic Oncology, 2010